Alaunos buys Velaris, raises $350m for lung drugs

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

The Florida biotech takes on a pulmonary hypertension pipeline backed by Fairmount, with cash it says should last into 2029.

Alaunos Therapeutics, based in Fort Lauderdale, has an obesity program at the center of how it describes itself. That program is ALN1003, an oral small molecule the company calls a non-hormonal, non-incretin approach. On 13 October, it announced something quite different: the completed acquisition of Velaris Therapeutics, a private company working on pulmonary arterial hypertension (PAH), meaning high blood pressure in the arteries of the lungs [1].

An oversubscribed private placement came with the deal. Fairmount led it, with Venrock Healthcare Capital Partners, T Rowe Price Investment Management, Wellington Management, Janus Henderson Investors, BB Biotech, Perceptive Advisors and others taking part. Alaunos sold Series C non-voting convertible preferred stock and says gross proceeds were approximately $350 million.

The company expects that to fund operations into 2029. On the list of things it should cover are proof-of-concept data for VLR199 in 2028, key datasets for VLR360, and initial regulatory filings for VLR247 and VLR258.

The drugs

Velaris is the ninth company launched from assets discovered by Paragon Labs, which Fairmount founded. Its lead, VLR199, is what the release calls an ActRIIA-Fc ligand trap. Think of a decoy that mops up signaling molecules before they reach their usual targets. It is meant to copy the pharmacology of the only approved activin-signaling inhibitor for PAH while improving on it where that therapy isn’t fully optimized.

VLR247 and VLR258 are also ligand traps, built to spare two molecules called BMP-9 and BMP-10, whose release ties to blood-related side effects. Then there is VLR360, an antibody aimed at PDGF-B, a different growth pathway. Velaris says it could be developed alone or paired with the traps. The release includes no human data on any of them.

Peter Harwin, a founding partner of Fairmount, joins the Alaunos board now. If stockholders later approve converting the new preferred stock into common stock, three current directors will resign and three Fairmount designees will take their seats. Harwin and those designees would then hold four of the five board seats. On an as-converted basis, Alaunos would have about 358.59 million shares of common stock. The closings themselves didn’t need a stockholder vote, but the conversion does, and Alaunos says it plans to file a proxy statement with the SEC first.

There is one more governance wrinkle. Once that approval comes through, holders of the Series B non-voting convertible preferred stock, voting as their own class, will be able to elect two of the five directors. Initially, those would be Harwin and one of the Fairmount designees, and the right lasts for as long as at least 30% of the originally issued Series B stock is still outstanding. Cantor is financial advisor to Alaunos. Wedbush Securities is strategic financial advisor to Velaris, with Jefferies, TD Cowen, Stifel, UBS Investment Bank and Wedbush & Co. acting as placement agents.

Dr Michael Henderson, President of Velaris, framed the market. “PAH and secondary pulmonary hypertension, including PH due to heart failure with preserved ejection fraction (PH-HFpEF) and interstitial lung disease (PH-ILD), significantly affect the lives of hundreds of thousands living with these conditions in the United States and even more globally,” he said.

“We believe this transaction and the concurrent private placement provide a strong financial foundation for us to advance an exciting pipeline and offer our stockholders a compelling opportunity to realize value, with proof-of-concept data for VLR199 expected in 2028,” Holger Weis, CEO and Chairman of the Board of Directors of Alaunos, said.

Heart and lung function carry a lot of weight in how well people keep going as they get older, and Velaris is openly aiming past PAH at the secondary forms tied to heart failure and lung scarring. That reach is a stated ambition and nothing more at this stage. Investors have put in a large sum for data that is two years off, and the stockholder meeting that sets the new board has no date in the release.


Wondering how often a big raise arrives wrapped in a reverse merger? Ask DLT to “list recent reverse mergers and private placements in clinical-stage biotech” or to “compare financing rounds led by specialist healthcare investors in cardiopulmonary disease” – explore the platform HERE.

[1] https://ir.alaunos.com/news-releases/news-release-details/alaunos-therapeutics-announces-acquisition-velaris-therapeutics

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Old dogs, new funding: Dog Aging Project fetches $29m from NIH

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE